New Approach to Weight Loss
Share
Obesity is a growing health problem around the world. Experts estimate that by 2035, more than 3 billion adults may be living with obesity. This condition increases the risk of many diseases, including heart disease, diabetes, and metabolic disorders. Because of this, scientists are constantly searching for better treatments that help people lose fat while keeping their muscles strong. A recent clinical trial explored a new combination of medicines that may help achieve this goal.
Why Weight Loss Treatments Need Improvement
Many weight loss strategies focus on reducing calorie intake. While this can lead to weight loss, it often causes loss of muscle along with fat. Research suggests that about 25 to 40 percent of the weight lost during dieting or medication can come from lean tissue such as muscle. Losing muscle is not ideal because it affects strength, physical function, and metabolism.
For this reason, researchers are interested in treatments that reduce body fat but protect muscle mass. Preserving muscle can help people stay active, maintain metabolic health, and prevent long term complications.
Understanding the Two Medications
The study examined two medications: bimagrumab and semaglutide. Each works in a different way.
Semaglutide is already used for treating obesity. It works by affecting the brain pathways that control appetite. People taking semaglutide usually feel less hungry and eat fewer calories. This leads to weight loss over time.
Bimagrumab works differently. It targets specific receptors involved in muscle growth and fat regulation. By blocking certain signals in the body, it helps reduce fat while encouraging muscle growth. Earlier research has shown that this drug can lower total body fat and visceral fat while increasing lean muscle mass.
Because the two medicines act through different mechanisms, researchers wanted to see if combining them could produce better results.
How the Study Was Conducted
The clinical trial included 507 adults with obesity. Participants either had a body mass index of 30 or higher, or a BMI of 27 with at least one obesity related health problem.
They were randomly divided into nine different groups. Some participants received placebo, some received bimagrumab alone, some received semaglutide alone, and others received both medications together. The treatment lasted for 48 weeks, with an extension period up to 72 weeks.
Researchers measured changes in body weight, body fat, muscle mass, and other health markers during the study.
Weight Loss Results
The results were promising. Participants taking semaglutide alone lost about 14.2 kilograms on average after 48 weeks. Those receiving high dose bimagrumab lost about 9.3 kilograms. However, the group receiving both medications experienced the greatest weight loss.
The high dose combination group lost around 17.8 kilograms after 48 weeks. By week 72, weight loss reached about 24 kilograms in this group.
Another interesting finding was that many participants achieved significant weight reduction. More than 60 percent of people in the high dose combination group lost at least 15 percent of their body weight.
Fat Loss and Muscle Preservation
One of the most important findings of the study was related to body composition. Many weight loss treatments reduce both fat and muscle. In this trial, the combination treatment produced a large reduction in fat mass while preserving more lean muscle compared with semaglutide alone.
Researchers also observed large reductions in visceral fat, which is the harmful fat stored around organs. Lower visceral fat is linked with improved metabolic health and lower risk of heart disease.
Effects on Blood Sugar and Health Markers
The study also looked at metabolic health. Participants using semaglutide and the combination therapy showed improvements in blood sugar levels. Some individuals with prediabetes returned to normal blood sugar ranges during the study.
Waist circumference also decreased significantly, especially in the combination group. This suggests a reduction in abdominal fat, which is an important marker of health risk.
Possible Side Effects
Like all medications, these treatments had some side effects. People taking bimagrumab sometimes experienced muscle cramps, diarrhea, or acne. Semaglutide was more commonly associated with nausea, constipation, fatigue, and diarrhea.
Overall, the safety profile of the combination therapy was consistent with the known effects of each drug. No deaths were reported during the trial.
What This Means for the Future of Obesity Treatment
This study suggests that combining medications with different mechanisms may be a powerful approach to treating obesity. The combination of bimagrumab and semaglutide not only produced significant weight loss but also helped preserve muscle mass.
More research will still be needed before this treatment becomes widely available. However, the results highlight an important shift in obesity care. Instead of focusing only on weight loss, future therapies may aim to improve body composition by reducing fat while maintaining muscle.
For people struggling with obesity, treatments that support both fat loss and muscle health could lead to better long term outcomes and improved quality of life.